Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 3/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20464122 | 0.91 | KMT2A (0.63) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29617446 | 0.91 | KMT2A (0.63) | KMT2AEPHX2FABP7FABP5CASP3 | |
| Hydrochloric Acid SCHEMBL29617452 | 0.90 | KMT2A (0.62) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL793384 | 0.89 | KMT2A (0.85) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL2906210 | 0.89 | KMT2A (0.68) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL18510205 | 0.88 | KMT2A (0.58) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL2898644 | 0.87 | KMT2A (0.73) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL5033236 | 0.87 | KMT2A (0.73) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL31135496 | 0.87 | KMT2A (0.73) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL12650693 | 0.86 | KMT2A (0.58) | KMT2AEPHX2TLR2FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230093861-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093861-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | KMT2A 2739/4885EPHX2 4829/4885TLR2 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.